Computed tomography is entering a major technology cycle, comparable to the earlier transition toward multidetector and dual-source systems. In 2026, the competitive question extends beyond how quickly a scanner can acquire an image. The industry is increasingly focused on how much useful information can be extracted from each examination, at what radiation and contrast dose, and with how little operational friction.
BIS Research projects the global computed tomography market to grow from $7,397.4 million in 2025 to $13,197.1 million by 2036, representing a CAGR of 5.47% from 2026 to 2036. Growth is being supported by rising imaging demand, expanding clinical applications, replacement of ageing systems, and investment in advanced detector and software platforms.
Explore the Computed Tomography Market before the next wave of imaging innovation reshapes competitive priorities and investment decisions.
Photon-counting CT is the most visible structural change in the market. Conventional energy-integrating detectors convert groups of X-ray photons into a combined signal. Photon-counting detectors register individual photons and measure their energy, producing higher spatial resolution, improved spectral information, lower electronic noise, and opportunities to reduce radiation or iodinated contrast exposure.
Clinical evidence is expanding across cardiac, thoracic, neurovascular, abdominal, musculoskeletal, paediatric, and oncological imaging. Research indicates improvements in diagnostic accuracy, reader confidence, image quality, and dose efficiency.
Manufacturers are also broadening their photon-counting portfolios, indicating that the technology is moving beyond a limited premium category and becoming a wider competitive platform. The long-term opportunity will depend on clinical validation, affordability, reimbursement, system availability, and the ability to integrate photon-counting CT into routine diagnostic workflows.
Spectral CT is becoming increasingly important in hospital purchasing decisions. By separating X-ray information at different energy levels, spectral systems can support material differentiation, iodine mapping, virtual monoenergetic imaging, and improved characterization of tissues and lesions.
Always-on spectral acquisition is particularly significant because it allows spectral data to become part of routine imaging rather than an additional protocol reserved for complex cases. This can improve first-time-right imaging, reduce repeat examinations, and strengthen diagnostic confidence across emergency, oncology, vascular, and cardiac pathways.
For hospitals, the value of spectral CT will increasingly be measured by its ability to reduce uncertainty, improve lesion characterization, and deliver clinically useful information without adding major workflow complexity.
Download the Complete TOC to see the technologies, market segments, clinical applications, and competitive opportunities covered in the report before making your next strategic decision.
Artificial intelligence in CT is moving beyond isolated image-processing features. Deep-learning reconstruction can reduce noise, preserve anatomical detail, and support lower-dose protocols. However, the larger opportunity lies in workflow orchestration.
AI is increasingly being applied to patient positioning, protocol selection, acquisition parameters, reconstruction, triage, quantitative analysis, and reporting support. For healthcare providers facing radiologist shortages and rising scan volumes, AI’s commercial value will be measured less by algorithm novelty and more by throughput, consistency, repeat-scan reduction, and time to diagnosis.
The systems that succeed will be those that reduce operational friction across the entire imaging pathway rather than improving only one stage of the examination.
Radiation optimization remains a central design priority because CT uses ionizing radiation. Examinations must be justified and optimized so the required diagnostic information is obtained with the lowest reasonably achievable exposure.
New detector architectures, automated exposure control, iterative reconstruction, and deep-learning reconstruction are making dose reduction increasingly compatible with high image quality. This is particularly relevant for paediatric imaging, lung cancer screening, cardiovascular examinations, and patients requiring repeated follow-up scans.
Low-dose performance is no longer a single product feature. It is becoming a system-level expectation shaped by detector efficiency, software quality, protocol automation, and clinical workflow design.
Request a Sample Report Now to access the market intelligence shaping product strategy, competitive positioning, and investment planning in computed tomography.
The next phase of computed tomography will not be defined by one technology. Market leadership will depend on combining advanced detectors, spectral capability, AI reconstruction, automated workflows, service infrastructure, and clinical evidence into scalable imaging platforms.
For manufacturers, the challenge is converting technical performance into measurable clinical and economic outcomes. For hospitals, the priority is selecting systems that improve diagnostic confidence while supporting productivity, interoperability, and long-term upgradeability.
In 2026, the future of CT is not simply sharper imaging. It is more informative, lower-dose, workflow-aware imaging that supports faster, more precise, and more consistent clinical decisions.
